TA 102
Alternative Names: TA-102Latest Information Update: 28 Feb 2023
At a glance
- Originator Taro Pharmaceuticals USA
- Class Antipsoriatics; Skin disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Plaque psoriasis
Most Recent Events
- 28 Feb 2023 No recent reports of development identified for phase-I development in Plaque-psoriasis(In volunteers) in USA (Topical)
- 29 Nov 2022 Taro Pharmaceuticals completes a phase I trial in Plaque Psoriasis (In volunteers) in USA (Topical) (NCT03645499)
- 23 Feb 2021 TA 102 is still in phase trials for Plaque psoriasis (In volunteers) in USA (Topical) (NCT03645499)